High Response Rates in Psoriasis With Oral IL-23 Inhibitor
An oral interleukin (IL)-23 inhibitor for psoriasis produced 16-week response rates as high as 79% in moderate-to-severe plaque psoriasis, a prospective phase II trial showed. The drug (JNJ-77242113) achieved response rates of 37% to 79% across five dose levels. In contrast, patients treated with placebo had a 9% response rate at 16 weeks. The most […]
Link Between Psoriasis, Heart Disease Tracks to Coronary Microvascular Dysfunction
Almost a third of patients with severe psoriasis had echocardiographic evidence of asymptomatic coronary microvascular dysfunction (CMD), a prospective study showed. Doppler echocardiography showed that 31.5% of 448 patients with psoriasis had CMD. Every 1-point increase in the Psoriasis Area and Severity Index (PASI) score and 1-year increase in psoriasis duration correlated with a 5% […]
Tool Predicts PsA Progression From Psoriasis, No Fancy Biomarkers Needed
A risk-prediction algorithm was modestly accurate for identifying patients with psoriasis who are likely to progress to psoriatic arthritis (PsA), researchers reported. Based on patients’ demographics and clinical presentations routinely assessed during office visits, the model was about 72% effective in predicting 1-year risk of progression, and 75% effective (using slightly different input data) for […]